Results 1 to 10 of about 2,997 (217)

Advances and challenges in immunoPET methodology [PDF]

Frontiers in Nuclear Medicine
Immuno-positron emission tomography (immunoPET) enables imaging of specific targets that play a role in targeted therapy and immunotherapy, such as antigens on cell membranes, targets in the disease microenvironment, or immune cells.
Philipp Mohr, Joyce van Sluis, Marjolijn N. Lub-de Hooge, Marjolijn N. Lub-de Hooge, Adriaan A. Lammertsma, Adrienne H. Brouwers, Charalampos Tsoumpas   +6 more
doaj   +8 more sources

Application of immunoPET imaging to enhance head and neck squamous cell carcinoma clinical management [PDF]

Frontiers in Oncology
BackgroundHead and neck squamous cell carcinoma (HNSCC) remains a significant clinical challenge due to high recurrence, therapy resistance, and limited biomarkers. The tumor microenvironment (TME) plays a critical role in determining treatment outcomes.
Waleed M. Almutairi, Waleed M. Almutairi, Qi-Huang Zheng, Mark Langer, Oluwaseyi M. Oderinde, Oluwaseyi M. Oderinde   +5 more
doaj   +3 more sources

89Zr-anti-CD8 immunoPET visualizes heterogeneous intratumoral CD8+ immune responses to treatment with radiation and anti-CTLA4 [PDF]

npj Imaging
Anti-CD8 immunoPET facilitates non-invasive, whole-body visualization of immune responses, and syngeneic preclinical models are a crucial tool for studying tumor infiltration of T cells in response to cancer therapies.
Elizabeth A. Germino, Kirstin A. Zettlitz, Tyler Watkins, Bao Ying Chen, Deirdre La Placa, Felix B. Salazar, Jennifer Chean, Shichang Li, Heather M. McGee, Terence M. Williams, Anna M. Wu   +10 more
doaj   +3 more sources

Advances in immunoPET/SPECT imaging: The role of Fab and F(ab′)2 fragments in theranostics [PDF]

Acta Pharmaceutica Sinica B
With the advent of precision medicine and personalized treatment, targeted therapies have become pivotal in oncology. Noninvasive molecular imaging, especially immunoPET/SPECT, plays a crucial role in refining cancer diagnostics and treatment monitoring ...
Wenpeng Huang, Jingwei Zhou, Yanchen Liu, Yihan Yang, Rachel J. Saladin, Jessica C. Hsu, Weibo Cai, Lei Kang   +7 more
doaj   +3 more sources

Ultra-low dose immunoPET using 64Cu-rituximab tracer for a human CD20 mouse model [PDF]

Frontiers in Medicine
Antibodies (Abs) and their fragments can be labeled with PET radioisotope (immunoPET) for in vivo diagnostic imaging. Compared to the conventional FDG-PET, immunoPET can be designed to target in vivo cancer-specific antigen expression levels for various ...
Frezghi Habte, Arutselvan Natarajan
doaj   +3 more sources

Zirconium 89 and Copper 64 for ImmunoPET: From Antibody Bioconjugation and Radiolabeling to Molecular Imaging [PDF]

Pharmaceutics
Immunotherapy has transformed cancer treatment. Nevertheless, given the heterogeneity of clinical efficacy, the multiplicity of treatment options available and the possibility of serious adverse effects, selecting the most effective treatment has become ...
Laure Badier, Isabelle Quelven
doaj   +3 more sources

Development of a toxin-selective immunotracer for in vivo detection of Clostridioides difficile infection by immunoPET [PDF]

EJNMMI Radiopharmacy and Chemistry
Background Clostridioides difficile infection (CDI) is a major healthcare challenge that is associated with high morbidity and mortality. Current diagnostic methods are limited in terms of specificity and invasiveness, necessitating novel, non-invasive ...
Mario González-Arjona, Lorena Cussó, Luis Alcalá, María Isabel González, Alexandra de Francisco, María Jesús Fernández-Aceñero, Dag Sehlin, Stina Syvänen, Emilio Bouza, Patricia Muñoz, Manuel Desco, Beatriz Salinas   +11 more
doaj   +3 more sources

89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors [PDF]

Pharmaceuticals, 2012
The human epidermal growth factor receptor 2 (HER2/neu) is overexpressed in 20–30% of breast cancers and is associated with tumor growth, angiogenesis, and development of distant metastases.
Albert J. Chang, Ravindra DeSilva, Sandeep Jain, Kimberley Lears, Suzanne Lapi, Buck Rogers   +5 more
doaj   +5 more sources

Detection of immune-mediated tumour cell death in vivo using Zirconium-89-labeled APOMAB® [PDF]

Journal of Translational Medicine
Background Inconsistent responses to anticancer immunotherapies demonstrate the need for non-invasive methods to detect treatment responses earlier than conventional medical imaging methods allow.
Vasilios Liapis, Nicole L. Wittwer, William Tieu, Tessa Gargett, Michael P. Brown, Alexander H. Staudacher   +5 more
doaj   +2 more sources

Preclinical development of novel PD-L1 tracers and first-in-human study of [68Ga]Ga-NOTA-RW102 in patients with lung cancers [PDF]

Journal for ImmunoTherapy of Cancer
Background The programmed cell death protein-1 (PD-1)/programmed death receptor ligand 1 (PD-L1) axis critically facilitates cancer cells immune evasion. Antibody therapeutics targeting the PD-1/PD-L1 axis have shown remarkable efficacy in various tumors.
Cheng Wang, Dong Xu, Jianjun Liu, Gang Huang, Haitao Zhao, You Zhang, Jonathan W Engle, Min Cao, Yanfei Wu, Sara Malih, Erpeng Yang, Muhsin H Younis, Wilson Lin, Qiufang Liu, Mohammad J Rasaee, Yihui Guan, Weibo Cai, Fang Xie, Weijun Wei   +18 more
doaj   +2 more sources